QRG Capital Management Inc. Increases Holdings in Eli Lilly and Company $LLY

Key Points

• QRG Capital Management increased its stake in Eli Lilly by 9.6% in Q4 to 113,411 shares valued at $121.88 million, making LLY its 11th‑largest position and 1.4% of the firm's portfolio.
• Strong quarterly results and guidance: Lilly reported a Q1 beat‑and‑raise (EPS $8.55 vs. $6.97 estimate; revenue $19.8B, +55.5% YoY), set FY2026 EPS guidance of 35.50–37.00, and carries a consensus "Moderate Buy" with a $1,217.59 target amid several analyst price‑target increases.
• Strategic catalysts and risks: the oral GLP‑1 pill Foundayo is showing early commercial traction and Lilly committed an additional $4.5B to Indiana manufacturing capacity, but the company faces intensifying competition from Novo Nordisk and reports it may sell roughly $8B of bonds to fund acquisitions.

QRG Capital Management Inc. boosted its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 9.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 113,411 shares of the company's stock after purchasing an additional 9,963 shares during the period. Eli Lilly and Company comprises 1.4% of QRG Capital Management Inc.'s investment portfolio, making the stock its 11th biggest position. QRG Capital Management Inc.'s holdings in Eli Lilly and Company were worth $121,880,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Exencial Wealth Advisors LLC lifted its stake in shares of Eli Lilly and Company by 189.6% during the third quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company's stock valued at $13,283,000 after buying an additional 11,396 shares during the period. Cidel Asset Management Inc. boosted its holdings in Eli Lilly and Company by 26.5% in the third quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company's stock valued at $20,392,000 after acquiring an additional 5,591 shares during the last quarter. Spire Wealth Management lifted its stake in shares of Eli Lilly and Company by 2.2% in the 4th quarter. Spire Wealth Management now owns 27,719 shares of the company's stock valued at $29,789,000 after purchasing an additional 592 shares in the last quarter. Coldstream Capital Management Inc. lifted its position in Eli Lilly and Company by 25.6% during the third quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company's stock valued at $32,365,000 after buying an additional 8,659 shares in the last quarter. Finally, Oak Family Advisors LLC acquired a new position in shares of Eli Lilly and Company during the 3rd quarter valued at $1,979,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have weighed in on LLY. The Goldman Sachs Group upped their price target on Eli Lilly and Company from $1,260.00 to $1,283.00 and gave the stock a "buy" rating in a report on Friday, May 1st. Argus lifted their price target on Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a "buy" rating in a research note on Monday, February 9th. UBS Group reaffirmed a "buy" rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. Jefferies Financial Group set a $1,300.00 target price on Eli Lilly and Company and gave the company a "buy" rating in a report on Friday, March 13th. Finally, Morgan Stanley restated an "overweight" rating and set a $1,344.00 price target on shares of Eli Lilly and Company in a research report on Friday, May 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $1,217.59.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Long‑term efficacy data for Omvoh (mirikizumab) — LUCENT‑3 open‑label data show ~63.5% of patients who achieved disease clearance at one year maintained it at four years, reinforcing Omvoh’s durability in ulcerative colitis and strengthening Lilly’s IL‑23 franchise revenue outlook. Eli Lilly Advances As Inflammatory Bowel Disease Drug Reinforces Long-Term Confidence
• Positive Sentiment: Foundayo oral GLP‑1 pill showing early commercial traction — reports say the oral obesity pill is adding prescribers and patients with broad pharmacy access and payer coverage, supporting a new revenue channel beyond injectables. Lilly's Oral GLP-1 Pill Foundayo Starts Strong in Oral Obesity Market
• Positive Sentiment: Major manufacturing expansion — Lilly committed an additional $4.5B in Indiana (over $21B total since 2020) and opened a genetic‑medicine facility, which supports capacity for anticipated demand across biologics, small molecules and advanced therapies. This is a long‑term enabler of supply reliability. Lilly commits additional $4.5 billion across Indiana manufacturing sites
• Positive Sentiment: Earnings momentum and analyst support — recent Q1 beat‑and‑raise (strong Mounjaro and Zepbound sales) and analyst reiterations/targets underpin bullish sentiment and justify elevated valuation multiples. LLY Stock Pops 16% After Beat-and-Raise Q1: Buy, Hold or Take Profits?
• Neutral Sentiment: Dividend declared ($1.73/share, ex‑dividend May 15) — modest yield (≈0.7%) signals shareholder returns but is not a major near‑term price driver. Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility
• Neutral Sentiment: Market chatter about financing — reports that Lilly is planning to sell roughly $8B of bonds to fund acquisitions could change capital structure and near‑term financing costs; company provided responses but investors will watch details. Update: Market Chatter: Eli Lilly Plans to Sell About $8 Billion of Bonds to Fund Acquisitions
• Negative Sentiment: Intense competition from Novo Nordisk — Novo’s strong pill launch and raised guidance highlight accelerating competitive pressure in the obesity/GLP‑1 market, which could cap pricing and market share gains for Lilly over time. Novo Nordisk Could Win the Oral GLP-1 Race Against Lilly. Why It Just Raised Guidance.
• Negative Sentiment: Market perception of product timing and pricing risk — coverage noting Novo’s momentum plus reports of delays/pressure in the oral GLP‑1 space raise short‑term uncertainty about Lilly’s obesity‑pill cadence and margin mix. Novo Nordisk Obesity Pill Momentum Meets Valuation Gap And Risk Flags

Eli Lilly and Company Price Performance

NYSE LLY opened at $987.52 on Thursday. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The company has a market cap of $929.98 billion, a PE ratio of 35.08, a PEG ratio of 1.08 and a beta of 0.48. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The stock's 50-day moving average price is $945.26 and its two-hundred day moving average price is $989.70.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same period in the previous year, the business earned $3.34 EPS. The company's revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, analysts predict that Eli Lilly and Company will post 35.58 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.